About Immune Targeting Systems
Immune Targeting Systems is a Healthcare company based in London (United Kingdom) founded in 2003, and was acquired by Altimmune in February 2015. T-cell vaccines against mutating viruses are discovered and developed. Immune Targeting Systems has raised $20.3 million across 2 funding rounds from investors including Altimmune, Truffle Capital and London Technology Fund. The company has 46 employees. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is ALTIMMUNE UK LIMITED.
Company details
Immune Targeting Systems was founded in 2003 in London, United Kingdom, within the biotechnology sector. Prophylactic and therapeutic vaccines targeting mutating viruses are developed using a fluorocarbon-conjugated synthetic peptide platform. Broad HLA and antigen coverage, along with product stability, are achieved in these T-cell vaccines. Protection against infectious diseases is provided, including Flunisyn as a depot vaccine for influenza. The company was acquired by Vaxin in February 2015.
- Headquarters London, United Kingdom
- Employees 46
- Stage Acquired
- SectorsHealthcare
- Website its-innovation.com
- Social LinkedIn
- Acquired by Altimmune (Feb 2015)
- Legal Name Altimmune Uk Limited
- Date of Incorporation 05 Oct, 1992
- Jurisdiction LEEDS, ENGLAND
Funding Insights of Immune Targeting Systems
Immune Targeting Systems has successfully raised a total of $20.3M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $13.2 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.3M
- Total Rounds 2
- Last Round Series A — $13.2M
- First Round $7.1M
(Jul 2007)
- Investors Count 4
All 2 funding rounds of Immune Targeting Systems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2010 | $13.2M | Series A | – | – | |
| Jul 2007 | $7.1M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Immune Targeting Systems
Immune Targeting Systems has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Altimmune, Truffle Capital and London Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Truffle Capital is recognized as a leading European venture capital firm. | 2001 | truffle.com | Paris, France | |
| londontechnologyfund.com | ||||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
| healthcap.eu | ||||
Vaccines for infectious diseases and solid tumors are developed. | 1997 | altimmune.com | Gaithersburg, United States |
Investor details for Immune Targeting Systems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Immune Targeting Systems
4 dated milestones of Immune Targeting Systems across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Immune Targeting Systems is founded.
- Funding First funding round of $7.1M.
- Funding Latest funding round, Series A, of $13.2M.
- Exit Acquired by Altimmune.
Web traffic of Immune Targeting Systems
Websites that share an audience with Immune Targeting Systems (its-innovation.com).
Websites whose visitors overlap most with Immune Targeting Systems. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immune Targeting Systems
Complete news archive for Immune Targeting Systems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immune Targeting Systems
Immune Targeting Systems was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Immune Targeting Systems is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Immune Targeting Systems is a funded company, having raised a total of $20.3M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.1M, raised on Jul 2007.
Immune Targeting Systems has 46 employees.
Immune Targeting Systems was founded in 2003 in London, United Kingdom, within the biotechnology sector. Prophylactic and therapeutic vaccines targeting mutating viruses are developed using a fluorocarbon-conjugated synthetic peptide platform. Broad HLA and antigen coverage, along with product stability, are achieved in these T-cell vaccines. Protection against infectious diseases is provided, including Flunisyn as a depot vaccine for influenza. The company was acquired by Vaxin in February 2015.
Immune Targeting Systems has 5 investors. Key investors include Altimmune, Truffle Capital, London Technology Fund, Novartis Venture Fund, and Healthcap.
Immune Targeting Systems operates through Altimmune Uk Limited.
Yes. Immune Targeting Systems was acquired by Altimmune in February 2015.